Practitioner's Docket No. U 015825-1

### JC10 Rec'd PCT/PTO 2 2 JUN 2005

#### Optional Customer No. Bar Code



PATENT TRADEMARK OFFICE

**CHAPTER II** 

# TRANSMITTAL LETTER TO THE UNITED STATES ELECTED OFFICE (EO/US) (ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

INTERNATIONAL APPLICATION NO.

1.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/ES2003/000666

29 DECEMBER 2003

10 JANUARY 2003

TITLE OF INVENTION

DEVICE FOR ASSAYING POLYMORPHISMS OF GENE XPD/ERCC2 FOR THE CORRECT ADMINISTRATION OF CHEMOTHERAPY FOR LUNG CANCER

APPLICANT(S)

- ROSELL COSTA, Rafael
- 2. TARON ROCA, Miguel

Mail Stop PCT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

ATTENTION: EO/US

NOTE: To avoid abandonment of the application, the applicant shall furnish to the USPTO, not later than the expiration of 30 months from the priority date: (1) a copy of the international application, unless it has been previously

#### **CERTIFICATION UNDER 37 C.F.R. 1.10\***

(Express Mail label number is mandatory.)
(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date <u>June 22, 2005</u>, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number <u>EV 480460300 US</u>, addressed to the: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

GERALDINE MARTI

(type or print name of person mailing paper)

Signature of person mailing paper

WARNING:

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

\*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Elected Office (EO/US)-page 1 of 9) 13-18

ISTE Rec'd PCT/PTO 22 Jun 2005

communicated by the International Bureau or unless it was originally filed in the USPTO; and (2) the basic national fee (see 37 C.F.R. § 1.492(a)). The 30-month time limit may not be extended. 37 C.F.R. § 1.495(a) and (b).

WARNING:

Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. §1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. §1.8.

NOTE: Documents and fees must be clearly identified as a submission to enter the national state under 35 USC 371 otherwise the submission will be considered as being made under 35 USC 111. 37 C.F.R. § 1.494(f).

- 1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:
  - a. [X] This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
  - b. [X] The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:
  - c. [ ] ADDED PAGES FOR APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED

NOTE: § 1.495 Entering the national stage in the United States of America.

- (a) The applicant in an international application must fulfill the requirements of 35 U.S.C 371 within the time periods set forth in paragraphs (b) and (c) of this section in order to prevent the abandonment of the international application as to the United States of America. The thirty month time period set forth in paragraphs (b), (c) (d), (e) and (h) of this section may not be extended. International applications for which those requirements are timely fulfilled will enter the national stage and obtain an examination as to the patentability of the invention in the United States of America.
- (b) To avoid abandonment of the application, the applicant shall furnish to the United Stats Patent and Trademark Office not later than the expiration of thirty months from the priority date:
- (1) A copy of the international application, unless it has been previously communicated by the International Bureau or unless it was originally filed in the United States Patent and Trademark Office; and
  - (2) The basic national fee (see § 1.492(a)).
- (c)(1) If applicant complies with paragraph (b) of this section before expiration of thirty months from the priority date, the Office will notify the applicant if he or she has omitted any of:
- (i) A translation of the international application, as filed, into the English language, if it was originally filed in another language (35 U.S.C. 371(c)(2));
- (ii) The oath or declaration of the inventor (35 U.S.C. 371(c)(4) and § 1.497), if a declaration of inventorship in compliance with § 1.497 has not been previously submitted in the international application under PCT Rule 4.17 (iv) within the time limits provided for in PCT Rule 26ter.1;
  - (ii) The search fee set forth in § 1.492(c); and
  - (iv) The examination fee set forth in § 1.492(c); and
  - (v) Any application size fee required by § 1.492(j)
- (2) A notice under paragraph (c)(1) of this section will set a period of time within which applicant must provide any omitted translation, oath or declaration of the inventor, search fee set forth in  $\S$  1.492(b), examination fee set

# 10/540047 JC18 Rec'd PCT/PTO 22 JUN 2065

forth in § 1.492(c), and any application size fee required by § 1.492(j) in order to avoid abandonment of the application.

(3) The payment of the processing fee set forth in § 1.492(i) is required for acceptance of English translation later than the expiration of thirty months after the priority date. The payment of the surcharge set forth in § 1.429(h) is required for acceptance of the oath or declaration the inventor later than the expiration of thirty months after the priority date.

#### 2. Fees

CLAIMS FEE *	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS*	9 - 20 =		x \$ 50.00 =	\$
	INDEPENDENT CLAIMS*	5 -3=	2	x \$ 200.00 =	400.00
İ	MULTIPLE DEPENDE	NT CLAIM(S) (if ap	plicable) + \$360.0	0	
FILING FEES**	[x] Basic filing [] Search fee p [x] Non-U.S. S [] No Search p [x] Exam Fee [] Exam fee w satisfied [] Additional p drawings fil sheets (exe or computer electronic m	paid to U.S. PTO learch Report filed Report or U. S. Search fee with U.S. IPER conditions fee for specification and led in paper over 100 cluding sequence listing r program listing filed in medium). The fee is \$250 ditional 50 sheets paper or		100.00) 400.00) 500.00) 200.00)	\$300.00
			Total of a	bove Calculations	= \$ 1,300.00
SMALL ENTITY	Reduction by ½ for filing filed. (note 37 CFR 1.9,	-			
		\$ 1,300.00			
				Total National Fee	\$ 1,300.00
	Fee for recording the end (See Item 13 below). See				
TOTAL			T	otal Fees enclosed	\$ 1,300.00

<sup>\*</sup>May include Preliminary Amendment (see page 8) reducing the number of claims.

## 10/540047

JC13 Rec d PC17PTO 22 JUN 2005

ii. [ ] Plea		Please	charge Account No. 12-0425 in the amount of \$  py of this sheet is enclosed.		
**WARNING:		"To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: $***(2)$ the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b).			
WARNING:		submitted met with forth in s months of acceptant comply v	If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.		
	[]	Asserti	on of Si	mall Entity Status	
	[]	Application [ ]		by asserts status as a small entity under 37 C.F.R. § 1.27 by. ement or Written Assertion attached.	
NOTE:	37 C.F.R or by pay	. § 1.27(d ment as d	c) deals w small en	rith the assertion of small entity status, whether by a written specific declaration thereof tity of the basic filing fee or the fee for the entry into the national phase as states:	
		should n entity st establish entitleme	nake a de atus base small er ent to sma	rmall entity status. Any party (person, small business concern or nonprofit organization) termination, pursuant to paragraph (f) of this section, of entitlement to be accorded small ed on the definitions set forth in paragraph (a) of this section, and must, in order to ntity status for the purpose of paying small entity fees, actually make an assertion of all entity status, in the manner set forth in paragraph (c)(1) or (c)(3) of this section, in the tent in which such small entity fees are to be paid.	
		(1)		on by writing. Small entity status may be established by a written assertion of entitlement l entity status. A written assertion must:	
			<i>(i)</i>	Be clearly identifiable;	
			(ii)	Be signed (see paragraph (c)(2) of this section); and	

(2) Parties who can sign and file the written assertion. The written assertion can be signed by:

to comply with the assertion requirement.

(iii)

(i) One of the parties identified in §§ 1.33(b) (e.g., an attorney or agent registered with the Office), §§ 3.73(b) of this chapter notwithstanding, who can also file the written assertion;

Convey the concept of entitlement to small entity status, such as by stating that

applicant is a small entity, or that small entity status is entitled to be asserted for the application or patent. While no specific words or wording are required to assert small entity status, the intent to assert small entity status must be clearly indicated in order

(ii) At least one of the individuals identified as an inventor (even though a §§ 1.63 executed oath or declaration has not been submitted), notwithstanding §§ 1.33(b)(4), who can also file the written assertion pursuant to the exception under §§ 1.33(b) of this part; or

(iii) An assignee of an undivided part (iii) in the internal of \$\frac{1}{2}\$ \$\frac{1

- (3) Assertion by payment of the small entity basic filing or basic national fee. The payment, by any party, of the exact amount of one of the small entity basic filing fees set forth in §§ 1.16(a), (f), (g), (h), or (k), or one of the small entity basic national fees set forth in §§ 1.492(a)(1), (a)(2), (a)(3), (a)(4) or (a)(5), will be treated as a written assertion of entitlement to small entity status even if the type of basic filing or basic national fee is inadvertently selected in error.
  - (i) If the Office accords small entity status based on payment of a small entity basic filing or basic national fee under paragraph (c)(3) of this section that is not applicable to that application, any balance of the small entity fee that is applicable to that application will be due along with the appropriate surcharge set forth in §§ 1.16(e) or §§ 1.16(l).
  - (ii) The payment of any small entity fee other than those set forth in paragraph (c)(3) of this section (whether in the exact fee amount or not) will not be treated as a written assertion of entitlement to small entity status and will not be sufficient to establish small entity status in an application or a patent."
- 3. [x] A copy of the International application as filed (35 U.S.C. 371(c)(2)):

is transmitted herewith.

a.

NOTE: Section 1.495 (b) was amended to require that the basic national fee and a copy of the international application must be filed with the Office by 30 months from the priority date to avoid abandonment "The International Bureau normally provides the copy of the international application to the Office in accordance with PCT Article 20. At the same time, the International Bureau notifies applicant of the communication to the Office. In accordance with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that the communication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant normally need only check to be sure the notice from the International Bureau has been received and then pay the basic national fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See item 14c below.

	b.	[]	is not required, as the application was filed with the United States Receiving
			Office.
	c.	[x]	has been transmitted
		i.	[x] by the International Bureau.
			Date of mailing of the application (from form PCT/IB/308):
		ii.	by applicant on
			Date
4.	[x]	A trai	nslation of the International application into the English language (35 U.S.C.
		371(c	(2)(2)):
	a.	[x]	is transmitted herewith.
	b.	ίí	is not required as the application was filed in English.
	c.	ίi	was previously transmitted by applicant on
	•	LJ	Date
	d.	[]	will follow.
		. ,	
			and the second of the second o

NOTE: 37 C.F.R. § 1.495(c): "If applicant complies with paragraph (b) of this section before expiration of thirty months from the priority date but omits... a translation of the international application, as filed, into the English language, if it was originally filed in another language (35 U.S.C. 371(c)(2))... applicant will be so notified and given a period of time within which to file the translation... in order to prevent abandonment of the application. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than the expiration of thirty months after the priority date.... A 'Sequence Listing' need not be translated if the "Sequence Listing' complies with PCT Rule 12.1(d) and the description complies with PCT Rule 5.2(b)."

5. [ ] Amendments to the claims of the International application under PCT Article 19 (35

## 10/540047

### JC1C Rec'd PCT/PTO 22 JUN 2005

U.S.C. 371(c)(3)):

The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36. 37 C.F.R. § 1.495(d): "A copy of any amendments to the claims made under PCT Article 19, and a translation of those amendments into English, if they were made in another language, must be furnished not later than the expiration of thirty months from the priority date. Amendments under PCT Article 19 which are not received by the expiration of thirty months from the priority date will be considered to be canceled." are transmitted herewith. a. have been transmitted b. [ ] by the International Bureau. [ ] Date of mailing of the amendment (from form PCT/IB/308): \_\_\_\_\_\_. ii. [ ] by applicant on \_ Date have not been transmitted as c. [x] applicant chose not to make amendments under PCT Article 19. Date of mailing of Search Report (from form PCT/ISA/210):12 May 2004 the time limit for the submission of amendments has not yet expired. ii. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1. 6. A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. [x]371(c)(3)): [ ] is transmitted herewith. a. will follow b. [ ] c. [x]is not required as the amendments were made in the English language. has not been transmitted for reasons indicated at point 5(c) above. d. 7. [x] A copy of the international examination report (PCT/IPEA/409) is transmitted herewith. [x] is not required as the application was filed with the United States Receiving [] Office. Annex(es) to the international preliminary examination report 8. [] is/are transmitted herewith. a. [] is/are not required as the application was filed with the United States b. [] Receiving Office.

9.	[ ]	A trans	nation of the annexes to the international preliminary examination report
NOTE:	(if applice months for from the	cable), if the property decessing f	e) "A translation into English of any annexes to an international preliminary examination report e annexes were made in another language, must be furnished not later than the expiration of <b>thirty</b> riority date. Translations of the annexes which are not received by the expiration of <b>thirty</b> months at may be submitted within any period set pursuant to paragraph (c) of this section accompanied see set forth in § 1.492(f). Annexes for which translations are not timely received will be considered
	a. b.	[ ] [x]	is transmitted herewith. is not required as the annexes are in the English language.
10.	[x] a.	An oatl U.S.C.	n or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35 115 was previously submitted by applicant on
	b. с.	[ ] i. ii.	is submitted herewith, and such oath or declaration  [ ] is attached to the application.  [ ] identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70.  will follow.
NOTE:	37 C.F.R the prior declarati applicati notified o of the ap	L. § 1.495( ity date b ion of inv ion under and given plication.	c): "If applicant complies with paragraph (b) of this section before expiration of thirty months from ut omits the oath or declaration of the inventor (35 U.S.C. 371(c)(4) and § 1.497), if a entorship in compliance with § 1.497 has not been previously submitted in the international PCT Rule 4.17(iv) within the time limits provided for in PCT Rule 26ter.1, applicant will be so a period of time within which to file the oath or declaration in order to prevent abandonment The payment of the surcharge set forth in § 1.492(e) is required for acceptance of the oath or nventor later than the expiration of thirty months after the priority date."
Other d	locumen	t(s) or in	formation included:
11.	[x] a. b. c. d. e.	An Inte 17(2)(a [x] [ ] [ ]	is transmitted herewith. has been transmitted by the International Bureau. Date of mailing (from form PCT/IB/308): is not required, as the application was searched by the United States International Searching Authority. will be transmitted promptly upon request. has been submitted by applicant on
12.	[x] a. b. c.	An Info [ ] [ ] [ x]	is transmitted herewith.  Also transmitted herewith is/are: Form PTO-1449 (PTO/SB/08A and 08B).  Copies of citations listed. will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c). was previously submitted by applicant on

### 10/540047 JC18 Rec'd PCT/PTO 22 JUN 2006-)

Date

[x]	Additional documents:	
a.	[x] Copy of request (PCT/RO/101)	
b.	[x] International Publication No. WO 2004/063395 A1	
	i. [x] Specification, claims and drawing	
	ii. [] Front page only	
c.	[x] Preliminary amendment (37 C.F.R. § 1.121)	
d.	[x] Other	
	FORM PCT/IPEA/408 (WRITTEN OPINION)	
	FORM PCT/IPEA/416	
	SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE	
	COPY AND/OR AMENDMENT PERTAINING THERETO FOR	
	BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE	
	AND/OR AMINO ACID SEQUENCE	
[x]	The above checked items are being transmitted	
a.	[x] before 30 months from any claimed priority date.	
b.	after 30 months.	
[ ]	Certain requirements under 35 U.S.C. 371 were previously submitted by the	
	applicant on	
	, namely:	

#### **AUTHORIZATION TO CHARGE ADDITIONAL FEES**

**WARNING**:

Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges if extra claims are authorized.

NOTE: "A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3).

NOTE:	"Amounts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable tim nor will the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, requested, by credit to a deposit account." 37 C.F.R. § 1.26(a).						
	[X]	may be	ommissioner is hereby authorized to charge e required by this paper and during the entire ant No. 12-0425				
		[X]	37 C.F.R. 1.492(a)(1) (basic filing fee)				
WARNII	NG:		Because failure to pay the national fee within 30 months without extension (37 C.F.R. $\S$ 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.				
		[ ] [ ]	37 C.F.R. 1.492(b) (search fee) 37 C.F.R. 1.492(b) (exam fee) 37 C.F.R. 1.492(b) (claim fees)				
NOTE:	be paid o in any no	or these cl otice of fe	al fees for excess or multiple dependent claims not pai laims cancelled by amendment prior to the expiration o se deficiency (37 C.F.R. § 1.492(d)), it might be best n possible when dealing with amendments after final ac	of the time period set for response by the PTO ot to authorize the PTO to charge additional			
		[X] [X] [X]	37 C.F.R. 1.16(s) (spec and drawing, each 37 C.F.R. 1.17 (application processing fee 37 C.F.R. 1.17(a)(1)-(5) (extension fees p	es)			
NOTE:	applicati notificati	ion pr ion of ch	requires "Notification of any change in loss of entitle ior to paying, or at the time of paying issue fee." ange of status must be made even if the fee is paid uired if the change is to another small entity.	From the wording of 37 C.F.R. § 1.28(b): (a)			
		[]	37 C.F.R. § 1.492(e) and (f) (surcharge for filing an English translation of an Internat months after the priority date).				
		[X]	Please credit any overpayments to deposit	ассоци 12-0425.			
			SIGN	ATURE OF PRACTITIONER			
Reg. No.: 25,858		58	<u>WIL</u>	LIAM R. EVANS or print name of practitioner)			
Tel. No.: (212)708-1930		P.O. A	Address				
Customer No.:				adas & Parry LLP			
			New	York, N.Y. 10023			

00140

PATENT TRADEMARK OFFICE



JC20 Rec 30776 22 JUN 2005

#### Practitioner's Docket No. U 015825-1

#### Optional Customer No. Bar Code



PATENT TRADEMARK OFFICE

CHAPTER II

# TRANSMITTAL LETTER TO THE UNITED STATES ELECTED OFFICE (EO/US) (ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/ES2003/000666 29 DECEMBER 2003 10 JANUARY 2003

TITLE OF INVENTION
DEVICE FOR ASSAYING POLYMORPHISMS OF GENE XPD/ERCC2 FOR THE CORRECT ADMINISTRATION OF CHEMOTHERAPY FOR LUNG CANCER
APPLICANT(S)

1. ROSELL COSTA, Rafael
2. TARON ROCA, Miguel

Mail Stop PCT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

**ATTENTION: EO/US** 

#### CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

#### **MAILING**

deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

with sufficient postage as first class mail.

Mailing Label No. EV 480460300 US (mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: <u>June 22, 2005</u>

GERALDINE MARTI

(type or print name of person certifying)

\*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Submission-Nucleotide and/or Amino Acid Sequence-page 1 of 6) 9-37

#### SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1.	[]	This re	eplies to the Office Letter DATED	
NO:	TE:	made, e.	papers are filed before the office letter issues, ade g., in addition to the name of the inventor and ti procedure, the serial number from the return post	equate identification of the original papers should be tle of invention, the filing date based on the "Express card or the attorney's docket number added.
		[ ]	A copy of the Office Letter is enclosed	l.
			IDENTIFICATION OF PERSON	N MAKING STATEMENT
2.	I,		WILLIAM R. EVANS (type or print name of per	rson signing below)
	sta	te the fo	ollowing:	
			ITEMS BEING S	UBMITTED
3.	Su	bmitted	herewith is/are	
			(check each item a	s applicable)
	A.	<b>[√</b> ]	"Sequence Listing(s)" for the nucleotic application. Each "Sequence Listing" 37 C.F.R. § 1.821(c) and 37 C.F.R. §	is assigned a separate identifier as required in
	B.	[] An	n amendment to the description and/or cl quence by use of the assigned identifier,	aims, wherein reference is made to the as required in 37 C.F.R. § 1.821(d).
	C.	form,		tted for this application in computer readable
			a accordance with the requirements of 37	
	D.	[ ] Pl	ease transfer to this application, in accoradable copy(ies) from applicant's other a	rdance with 37 C.F.R. § 1.821(e), the computer application identified as follows:
		Se	re application of: erial No.: led: or:	Group No.: Examiner:



The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

"Sequence Identifier"

(other applications)

(this application)

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. 1.821(e).

- E. [✓] A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(f).
  - [ ] Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. § 1.821(b).
- F. [1] Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.
  - [ ] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).

# STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [1] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [1] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

5.	Applicant is		
	[ ] a small entity. A statement:		
	[ ] is attached.		
	[ ] was already filed.		
	[✓] other than a small entity.		

#### **EXTENSION OF TERM**

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b) as applicable)

(a) [ ] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity		ee for
[]	one month two months three months four months	\$120.00 \$450.00 \$1,020.00 \$1,590.00	\$ \$ \$	60.00 225.00 510.00 795.00

Fee \$

If an additional extension of time is required, please consider this a petition therefor.

(Submission-Nucleotide and/or Amino Acid Sequence-page 4 of 6) 9-37

(check and complete the next item, if applicable)

	[]		months has already been secured, and the fee paid therefor ed from the total fee due for the total months of extension now
			Extension fee due with this request \$
			OR
(b)	[ <b>√</b> ]	petition is being made	t no extension of term is required. However, this conditional to provide for the possibility that applicant has inadvertently a petition and fee for extension of time.
			FEE PAYMENT
3. []	Attach	ed is a check in the sum	of\$
. []	_	e Account No. licate of this transmittal i	the sum of \$ . s attached.
			FEE DEFICIENCY
9. NOTE:	the addi before t authoriz Branch	itional time consumed in mak the deficiency is noted and cation to charge is included, p in order to apply these charge	no authorization to charge an account, additional fees are necessary to cover ing up the original deficiency. If the maximum, six-month period has expired corrected, the application is held abandoned. In those instances where rocessing delays are encountered in returning the papers to the PTO finance s prior to action on the cases. Authorization to charge the deposit account for See the Notice of April 7, 1986, 1065 O.G. 31-33.
10. [X]	] If	any additional extension	and/or fee is required, charge Account No. 12-0425.



## SIGNATURE (S)C20 Rec'd PCT/PTO 22 JUN 2005

(type or print name of person signing statement)

Signature

Date	
P.O. Address of Signatory	
(If applicable)  Tel. No.: ( )  Reg. No.	[ ] Inventor [ ] Assignee of complete interest [ ] Person authorized to sign on behalf of assignee [ ] Practitioner of record [ ] Filed under Rule 34(a) [X] Registration No. 25,858 [ ] Other
(complete the following, if a	applicable)
FUNDACIÓN PARA LA INVESTIGACIÓN CLINICA Y MOLECULAR (type name of assignee)	DEL CANCER DE PULMON
VILLAROEL, 251, PRAL 2 <sup>a</sup> Address of assignee	
08036 BARCELONA, SPAIN	
Title of person authorized to sign on behalf of assignee	
A "STATEMENT UNDER 37 C.F.R. 3.73(b)" is attached.	
Assignment recorded in PTO on Reel Frame	
	SIGNATURE OF PRACTITIONER
Reg. No. 25,858	WILLIAM R. EVANS (type or print name of practitioner)
Tel. No.: (212)708-1930	LADAS & PARRY P.O. Address
Customer No.: 00140	26 WEST 61 <sup>ST</sup> STREET NEW YORK, N.Y. 10023
Customer No.:  00140	

٠٠رّ

PATENT TRADEMARK OFFICE